头颈部癌症患者牙科与颅面骨整合种植体的结局
回顾性审计评估头颈部癌症治疗中接受牙科或颅面骨整合种植体患者的结局。54例患者共植入160枚种植体,平均随访25.7个月后总体成功率85%。种植体品牌与生存率显著相关,眶部种植体生存率低于非眶部;非吸烟者和未接受放疗者种植体生存优势无统计学意义。
要点
- 头颈部癌症患者牙科与颅面骨整合种植体总体成功率85%,平均随访25.7个月。
- 种植体品牌与种植体生存率差异有统计学意义。
- 眶部种植体生存率低于非眶部种植体。
核心结论
- 牙科与颅面骨整合种植体可可靠用于头颈部癌症患者,但需进一步研究明确吸烟在种植体失败中的作用。
研究设计与样本
- 回顾性审计,回顾接受牙科或颅面骨整合种植体治疗的头颈部癌症患者的治疗情况。
- 共54例患者植入160枚种植体,患者有口腔、鼻、眶或耳部缺损。
主要发现
- 平均随访25.7个月后,总体85%的种植体成功。
- 所用种植体品牌与种植体生存率差异有统计学意义。
- 眶部种植体生存率低于非眶部种植体。
- 非吸烟者和未接受放疗者的种植体生存优势无统计学意义。
临床怎么用
- 作者认为牙科与颅面骨整合种植体可可靠用于头颈部癌症患者。
- 作者指出需进一步研究明确吸烟在骨整合种植体失败中的作用。
局限性
- 作者指出需进一步研究明确吸烟在骨整合种植体失败中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of head and neck cancer may result in disfiguring and debilitating anatomical changes. Osseointegrated implants may be used in these patients to facilitate attachment of implant-retained dentures or cosmetic prostheses. METHODS: A retrospective audit was performed, reviewing the treatment of patients who received dental or craniofacial osseointegrated implants during treatment of head and neck cancer. RESULTS: One hundred sixty implants were inserted in 54 patients with oral, nasal, orbital, or auricular defects. Overall, 85% of implants were successful after mean follow-up of 25.7 months. The brand of implant used was shown to impart a statistically significant implant survival difference, and orbital implants had poorer survival compared to nonorbital implants. There was a statistical insignificant implant survival advantage in both nonsmokers and patients who did not undergo radiotherapy. CONCLUSIONS: Dental and craniofacial osseointegrated implants may be reliably used in patients with head and neck cancer. However, further research is required to clarify the role of smoking in osseointegrated implant failure.
引用
- Moore P, Grinsell D, Lyons B, et al. Outcomes of dental and craniofacial osseointegrated implantation in head and neck cancer patients. Head Neck. 2019. PMID: 31215724. doi:10.1002/hed.25845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。